What antibiotic regimen should be used for a wound infection, including options for penicillin‑allergic patients and MRSA risk?

Antibiotic Treatment for Wound Infections

For methicillin-susceptible Staphylococcus aureus (MSSA) wound infections, use cefazolin 1 g IV every 8 hours or dicloxacillin 500 mg PO four times daily; for MRSA, use vancomycin 30 mg/kg/day IV in 2 divided doses or daptomycin 4 mg/kg IV daily. 1

Treatment Algorithm Based on Infection Severity and MRSA Risk

Mild Infections (Outpatient Management)

For simple wound infections without systemic signs:

MSSA-suspected infections:

• First-line: Cephalexin 500 mg PO four times daily OR dicloxacillin 500 mg PO four times daily 1
• Penicillin-allergic (non-anaphylactic): Cephalexin 500 mg PO four times daily 1
• Penicillin-allergic (anaphylaxis/hives): Clindamycin 300-450 mg PO four times daily 1

MRSA-suspected or confirmed infections:

• First-line options: Doxycycline 100 mg PO twice daily, clindamycin 300-450 mg PO four times daily, OR trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily 1
• Recent network meta-analysis suggests linezolid may achieve superior clinical success rates compared to vancomycin for MRSA skin infections (RR 1.71; 95%-CI 1.45-2.02), though it carries higher adverse reaction rates 2

Important caveat: Clindamycin has potential for cross-resistance with erythromycin-resistant strains and inducible resistance in MRSA—verify local susceptibility patterns 1

Moderate to Severe Infections (Inpatient Management)

For infections with systemic inflammatory response (fever >38°C or <36°C, tachycardia >90 bpm, tachypnea >24 breaths/min, WBC >12,000 or <4,000 cells/µL):

MSSA infections:

• First-line: Nafcillin or oxacillin 1-2 g IV every 4 hours 1
• Alternative (more convenient, less bone marrow suppression): Cefazolin 1 g IV every 8 hours 1
• Penicillin-allergic (anaphylaxis): Vancomycin 30 mg/kg/day IV in 2 divided doses 1

MRSA infections:

• First-line: Vancomycin 30 mg/kg/day IV in 2 divided doses 1
• Alternatives: Daptomycin 4 mg/kg IV every 24 hours (monitor for myopathy), linezolid 600 mg IV/PO every 12 hours, OR ceftaroline 600 mg IV twice daily 1
• A 2024 network meta-analysis found telavancin achieved better clinical microbiological success than vancomycin (RR 0.74; 95%-CI 0.55-0.99) 2

Surgical Site Infections

For clean wounds (trunk, head, neck, extremities) with systemic illness:

• Temperature >38°C AND WBC >12,000 AND erythema >5 cm from incision with induration or necrosis
• Start: Cefazolin OR vancomycin (if high MRSA prevalence in your institution) 1

For perineal wounds or GI/female genital tract operations:

• Start: Cephalosporin + metronidazole OR levofloxacin + metronidazole OR carbapenem 1

Critical Management Principles

Source Control is Mandatory

Incision and drainage is the primary treatment for abscesses, carbuncles, and large furuncles (strong recommendation, high-quality evidence) 1. Antibiotics alone are insufficient without adequate debridement of devitalized tissue and drainage of fluid collections 3.

Culture and Susceptibility Testing

• Obtain Gram stain and culture from carbuncles and abscesses (strong recommendation, moderate evidence) 1
• Do NOT culture inflamed epidermoid cysts (strong recommendation, moderate evidence) 1
• Adjust antibiotics based on susceptibility results—empiric broad-spectrum coverage should be narrowed once organisms are identified

Duration of Therapy

Standard duration is 7 days for uncomplicated infections 1. While clinical trials often used 10-day courses, there is no evidence this is superior to 7 days 4.

Special Considerations for Penicillin Allergy

The distinction between allergy types is critical:

• Non-anaphylactic reactions (rash only): First-generation cephalosporins (cefazolin, cephalexin) are safe 1
• Type 1 hypersensitivity (anaphylaxis, hives, angioedema): Avoid all β-lactams; use vancomycin (IV) or clindamycin (oral/IV) 1

Do not use macrolides (erythromycin) as empiric therapy due to widespread resistance in both S. aureus and β-hemolytic streptococci—clindamycin is the preferred alternative 3

MRSA Risk Assessment

Consider MRSA coverage when:

• Previous MRSA infection or colonization
• Recent hospitalization or healthcare exposure
• Injection drug use
• Failed initial antibiotic therapy
• Presence of purulent drainage
• Local MRSA prevalence >10-15% 1, 5

Recent surveillance data shows MRSA accounts for 34.7-68.5% of S. aureus wound isolates in various settings 6, 7, 8, making empiric MRSA coverage increasingly important in moderate-to-severe infections.

Topical Therapy for Limited Lesions

For patients with few lesions (impetigo, small wounds):

• Retapamulin ointment applied twice daily OR mupirocin ointment twice daily 1
• Animal model data suggests topical retapamulin and mupirocin are significantly more effective than systemic linezolid or vancomycin for superficial MRSA skin wounds 9

Common Pitfalls to Avoid

1. Using vancomycin for MSSA: Once susceptibilities confirm MSSA, switch to cefazolin or nafcillin—vancomycin is inferior for MSSA and promotes resistance 5

2. Inadequate source control: Antibiotics cannot penetrate walled-off abscesses—surgical drainage is essential 1, 3

3. Overlooking metastatic infection: In severe S. aureus bacteremia from wound sources, obtain echocardiography and image for vertebral osteomyelitis, epidural abscess, or septic arthritis 5

4. Ignoring local resistance patterns: Recent data shows high resistance to 2nd-generation cephalosporins and penicillins in both Gram-positive and Gram-negative wound pathogens—culture-guided therapy is essential 6, 8

5. Clindamycin for MRSA without susceptibility testing: Inducible clindamycin resistance occurs in erythromycin-resistant MRSA strains 1